|
|
Article: Monitors Say Northfield Trial Of PolyHeme Can Continue.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
The very preliminary success of a clinical trial usually isn't big news. But don't tell that to Northfield Laboratories Inc.
The Evanston, Ill.-based company reported the recommendation by an independent monitoring group to move ahead, without modification, with its pivotal Phase III study of PolyHeme - a human hemoglobin-based oxygen carrier.
And that go-ahead "is a big deal," said Steven Gould, Northfield's chairman and CEO. The OK to move forward comes after the group's initial review of blinded data on mortality and serious adverse events in the study.
"It's a big deal, if you've been following this," Gould told ...